Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a stock that investors should take a bite out of.

After finishing at $34.62 in the prior trading day, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) closed at $36.97, up 6.79%. In other words, the price has increased by $+2.35 from its previous closing price. On the day, 636831 shares were traded. AMLX stock price reached its highest trading level at $37.01 during the session, while it also had its lowest trading level at $33.30.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

Our goal is to gain a better understanding of AMLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.30 and its Current Ratio is at 5.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on May 25, 2022, initiated with a Buy rating and assigned the stock a target price of $21.

On April 01, 2022, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $36 to $10.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 when VIKING GLOBAL INVESTORS LP sold 700,000 shares for $30.23 per share. The transaction valued at 21,159,753 led to the insider holds 1,850,940 shares of the business.

VIKING GLOBAL INVESTORS LP sold 700,000 shares of AMLX for $20,559,887 on Sep 08. The 10% Owner now owns 2,075,470 shares after completing the transaction at $29.37 per share. On Jul 06, another insider, ALS Invest 1 B.V., who serves as the 10% Owner of the company, sold 60,609 shares for $20.70 each. As a result, the insider received 1,254,642 and left with 5,895,280 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 8097.66 while its Price-to-Book (P/B) ratio in mrq is 15.03.

Stock Price History:

Over the past 52 weeks, AMLX has reached a high of $38.76, while it has fallen to a 52-week low of $6.51. The 50-Day Moving Average of the stock is 33.17, while the 200-Day Moving Average is calculated to be 22.38.

Shares Statistics:

The stock has traded on average 1.57M shares per day over the past 3-months and 812.27k shares per day over the last 10 days, according to various share statistics. A total of 58.53M shares are outstanding, with a floating share count of 49.98M. Insiders hold about 24.57% of the company’s shares, while institutions hold 65.70% stake in the company. Shares short for AMLX as of Oct 13, 2022 were 6.7M with a Short Ratio of 5.36M, compared to 3.68M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.44% and a Short% of Float of 23.53%.

Earnings Estimates

Its stock is currently analyzed by 4 different market analysts. The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.67 and low estimates of -$1.03.

Analysts are recommending an EPS of between -$3.5 and -$3.86 for the fiscal current year, implying an average EPS of -$3.65. EPS for the following year is -$1.82, with 4 analysts recommending between $0.17 and -$3.67.

Revenue Estimates

A total of 4 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $6.75M, while the lowest revenue estimate was $590k, resulting in an average revenue estimate of $2.81M. In the same quarter a year ago, actual revenue was $285k, up 886.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $170.95M in the next fiscal year. The high estimate is $244.7M and the low estimate is $124.67M. The average revenue growth estimate for next year is up 5,983.60% from the average revenue estimate for this year.